Skip to main content

Table 6 Clinical parameters

From: Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Parameters Baseline Week 14 Change P value
HbA1c (NGSP, %) 7.8 ± 0.7 (184) 7.3 ± 0.8 (181) − 0.6 ± 0.7 (178) < 0.001
HbA1c (mmol/mol) 62.1 ± 7.5 (184) 55.9 ± 8.7 (181) − 6.2 ± 7.5 (178) < 0.001
Fasting plasma glucose (mg/dl) 156.2 ± 39.6 (136) 137.2 ± 29.9 (147) − 18.5 ± 39.5 (126) < 0.001
Body weight (kg) 82.5 ± 14.6 (175) 80.7 ± 14.8 (173) − 2.3 ± 2.8 (160) < 0.001
BMI (kg/m2) 30.0 ± 4.4 (175) 29.3 ± 4.4 (172) − 0.8 ± 1.0 (160) < 0.001
Abdominal circumference (cm) 100.0 ± 11.6 (184) 98.3 ± 11.1 (178) − 1.7 ± 4.5 (175) < 0.001
Body fat percentage (%) 33.5 ± 7.7 (172) 33.7 ± 7.9 (172) − 0.4 ± 2.4 (156) 0.06
Body fat (kg) 27.8 ± 8.8 (172) 27.4 ± 9.1 (171) − 1.0 ± 2.7 (156) < 0.001
Lean body mass (kg) 54.8 ± 10.9 (172) 53.3 ± 10.8 (171) − 1.3 ± 2.3 (156) < 0.001
Muscle mass (kg) 51.8 ± 10.4 (172) 50.5 ± 10.3 (172) − 1.2 ± 2.2 (156) < 0.001
Body water (kg) 36.7 ± 6.3 (172) 35.8 ± 6.4 (172) − 0.8 ± 1.9 (156) < 0.001
Bone mass (kg) 3.0 ± 0.5 (172) 2.9 ± 0.5 (171) − 0.1 ± 0.2 (156) < 0.001
Basal metabolic rate (kcal) 1585.8 ± 296.2 (172) 1543.2 ± 292.4 (171) − 41.5 ± 73.0 (156) < 0.001
TC (mg/dl) 184.9 ± 33.1 (146) 185.9 ± 32.0 (158) − 0.1 ± 24.9 (141) 0.94
HDL-C (mg/dl) 47.1 ± 11.1 (166) 47.9 ± 10.9 (169) 0.9 ± 6.3 (158) 0.08
LDL-C (mg/dl) 108.3 ± 29.8 (129) 108.5 ± 27.1 (141) − 1.1 ± 22.0 (118) 0.59
TG (mg/dl) 135.0 [99.0, 178.0] (133) 127.0 [93.0, 174.0] (145) 0.0 [− 30.0, 21.0] (123) 0.35
AST (IU/l) 32.5 ± 18.4 (171) 27.4 ± 14.0 (167) − 5.1 ± 12.9 (160) < 0.001
ALT (IU/l) 46.0 ± 30.4 (171) 37.6 ± 26.2 (167) − 8.4 ± 19.2 (161) < 0.001
γGTP (IU/l) 43.0 [29.0, 69.0] (157) 33.0 [24.0, 56.0] (153) − 6.0 [− 18.0, 0.0] (147) < 0.001
Serum creatinine (mg/dl) 0.72 ± 0.19 (173) 0.75 ± 0.20 (168) 0.02 ± 0.09 (162) 0.001
Uric acid (mg/dl) 5.5 ± 1.5 (169) 5.1 ± 1.3 (174) − 0.4 ± 0.8(162) < 0.001
Amylase (IU/l) 62.2 ± 33.0 (116) 66.6 ± 33.8 (120) 3.3 ± 16.4 (104) 0.040
RBC (× 104/μl) 487.0 ± 47.5 (160) 509.5 ± 45.6 (161) 23.0 ± 25.3 (151) < 0.001
WBC (/μl) 7211.7 ± 1760.1 (160) 7174.3 ± 1856.8 (161) 27.5 ± 1369.5 (151) 0.81
Hemoglobin (g/dl) 14.5 ± 1.6 (160) 15.1 ± 1.6 (161) 0.6 ± 0.8 (151) < 0.001
Hematocrit (%) 43.5 ± 4.2 (160) 45.8 ± 4.5 (161) 2.4 ± 2.6 (151) < 0.001
Platelet (× 104/μl) 24.3 ± 6.5 (160) 24.4 ± 6.4 (161) 0.1 ± 3.2 (151) 0.76
Urinary albumin/Cr (mg/g Cr) 14.9 [7.8, 32.4] (105) 16.0 [7.7, 34.5] (110) 0.3 [− 5.5, 7.0] (85) 0.64
Urinary albumin (mg/l) 16.6 [4.6, 47.6] (50) 13.3 [7.0, 39.6] (60) − 2.2 [− 12.4, 0.7] (41) 0.07
Urinary creatinine (mg/dl) 129.0 ± 73.7 (48) 89.8 ± 47.3 (63) − 33.2 ± 76.3 (42) 0.007
Systolic blood pressure (mmHg) 132.3 ± 14.1 (183) 129.8 ± 14.5 (181) − 2.7 ± 13.7 (178) 0.011
Diastolic blood pressure (mmHg) 80.6 ± 11.9 (183) 79.0 ± 12.2 (181) − 1.6 ± 10.4 (178) 0.047
  1. Data are shown as mean ± SD (n) with P values by one-sample t-test, or median [Q1, Q3] (n) with P values by Wilcoxon signed-rank test
  2. HbA1c glycosylated hemoglobin, NGSP national glycohemoglobin standardization program, BMI body mass index, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, TG triglyceride, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyl transpeptidase, RBC red blood cells, WBC white blood cells